TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib

被引：0
|
作者：
Kito, Yosuke [1 ]
Hamauchi, Satoshi [1 ]
Yamazaki, Kentaro [1 ]
Komori, Azusa [2 ]
Masuishi, Toshiki [2 ]
Taniguchi, Hiroya [2 ]
Mori, Keita [3 ]
Muro, Kei [2 ]
Yasui, Hirofumi [1 ]
机构：
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Nagaizumi, Shizuoka, Japan
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Shizuoka Canc Ctr, Clin Res Ctr, Nagaizumi, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O1 - 8 - 3
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
    Chen, Duke
    Wu, Yu-Shen
    Lin, Huapeng
    Wang, Yihan
    Li, Longhao
    Zhang, Tao
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2915 - 2924
  • [42] A multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE)
    Nishina, T.
    Kuboki, Y.
    Shinozaki, E.
    Yamazaki, K.
    Kajiwara, T.
    Shitara, K.
    Matsumoto, T.
    Tsushima, T.
    Okamoto, W.
    Mochizuki, N.
    Nomura, S.
    Sato, A.
    Ohtsu, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2015, 26
  • [43] A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (Ntask force: EPOC1410)
    Yamazaki, K.
    Kuboki, Y.
    Shinozaki, E.
    Hara, H.
    Komatsu, Y.
    Nishina, T.
    Yamaguchi, K.
    Yuki, S.
    Bando, H.
    Asayama, M.
    Tsushima, T.
    Hamauchi, S.
    Nakatsumi, H.
    Kajiwara, T.
    Wakabayashi, M.
    Nomura, S.
    Sato, A.
    Doi, T.
    Ohtsu, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer
    Jalali, A.
    Gard, G.
    Banks, S.
    Dunn, C.
    Wong, H. L.
    Wong, R.
    Lee, M.
    Gately, L.
    Loft, M.
    Shapiro, J. D.
    Kosmider, S.
    Tie, J.
    Ananda, S.
    Yeung, J. M.
    Jennens, R.
    Lee, B.
    McKendrick, J.
    Lim, L.
    Khattak, A.
    Gibbs, P.
    CURRENT PROBLEMS IN CANCER, 2022, 46 (02)
  • [45] Regorafenib with TAS-102 in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY)
    Moehler, M.
    Stein, A.
    Trojan, J.
    Marquardt, J.
    Quidde, J.
    Waidmann, O.
    Weinmann, A.
    Woerns, M.
    Schroeder, H.
    Maenz, M.
    Karatas, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S214 - S214
  • [46] Metastatic colorectal cancer patients who achieved long progression-free survival by regorafenib or TAS-102 therapy
    Kito, Yosuke
    Hamauchi, Satoshi
    Yamazaki, Kentaro
    Komori, Azusa
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Mori, Keita
    Muro, Kei
    Yasui, Hirofumi
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis
    Abrahao, Ana B. K.
    Ko, Yoo-Joung
    Berry, Scott
    Chan, Kelvin K. W.
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 113 - 120
  • [48] TAS-102 plus bevacizumab in metastatic colorectal cancer Reply
    Pfeiffer, Per
    Moller, Soren
    Winther, Stine Braendegaard
    Qvortrup, Camilla
    LANCET ONCOLOGY, 2020, 21 (05): : E227 - E227
  • [49] Neutropenia as a predictive factor in patients with metastatic colorectal cancer treated with TAS-102
    Hamauchi, S.
    Yamazaki, K.
    Masuishi, T.
    Kito, Y.
    Komori, A.
    Tsushima, T.
    Todaka, A.
    Yokota, T.
    Machida, N.
    Fukutomi, A.
    Onozawa, Y.
    Muro, K.
    Yasui, H.
    Mori, K.
    Taniguchi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 50 - 51
  • [50] Effectiveness of TAS-102 in patients with metastatic colorectal cancer in a single comprehensive cancer center
    Sales, C.
    Juliao, I.
    Rosinha, A.
    Marques, D.
    Carneiro, F.
    Faustino, C.
    Machado, M.
    Ferreira, P.
    Fragoso, M.
    Sousa, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 79 - 79
12345